Clear Scientific News

Cambridge, MA | Oct 2026 PRNewswire/-- Clear Scientific, Inc. announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates fentanyl, subsequently accelerating its removal from the body into urine. The results provide validation of CS-1103's novel mechanism of action. The trial met all endpoints, with CS-1103 accelerating the removal of fentanyl in human subjects and showing a favorable safety profi

Cambridge MA | Sept 2024 CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Clear Scientific, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions and diseases caused by an excess of harmful substances in the body, today announced positive topline data from the First-in-Human Phase 1 clinical trial of its therapeutic CS-1103 that demonstrate a favorable safety and tolerability profile. All thirty-two healthy participants recruited, d

Cambridge, MA | Oct 2023 Clear Scientific Inc., a Cambridge MA based biopharmaceutical company, announced that the FDA has approved its Investigational New Drug (IND) application for CS-1103, the first antidote for stimulant overdose, granting the company permission to initiate its Phase 1 First-in-Human clinical trial. Overdose from the stimulants methamphetamine and cocaine alone result in over 1,000,000 emergency department visits per year, with over 60,000 deaths, costin